Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jul 22;109(3):309-19.
doi: 10.1161/CIRCRESAHA.110.231233.

G protein coupled receptor kinases as therapeutic targets in cardiovascular disease

Affiliations
Review

G protein coupled receptor kinases as therapeutic targets in cardiovascular disease

Stephen L Belmonte et al. Circ Res. .

Abstract

G protein-coupled receptors (GPCRs) represent the largest family of membrane receptors and are responsible for regulating a wide variety of physiological processes. This is accomplished via ligand binding to GPCRs, activating associated heterotrimeric G proteins and intracellular signaling pathways. G protein-coupled receptor kinases (GRKs), in concert with β-arrestins, classically desensitize receptor signal transduction, thus preventing hyperactivation of GPCR second-messenger cascades. As changes in GRK expression have featured prominently in many cardiovascular pathologies, including heart failure, myocardial infarction, hypertension, and cardiac hypertrophy, GRKs have been intensively studied as potential diagnostic or therapeutic targets. Herein, we review our evolving understanding of the role of GRKs in cardiovascular pathophysiology.

PubMed Disclaimer

Figures

Figure 1
Figure 1. G Protein-Coupled Receptor (GPCR) Activation
Generalized schematic for GPCR activation. Upon ligand binding to the GPCR, the receptor undergoes a conformational change whereby the α subunit of its associated G protein is activated by exchanging bound GDP for GTP. The α and βγ subunits of the G protein subsequently dissociate to activate their respective downstream signaling cascades. For a more comprehensive overview of the complex variety of GPCR signaling cascades, please refer to Neves et al.. Abbreviations: PKA, protein kinase A; PYK, protein-rich tyrosine kinase; MEK5, Mitogen/extracellular signal regulated kinase kinase-5; PI3K, phosphatidylinositol-3 kinase; GRK, G protein-coupled receptor kinase; GIRK, G protein-activated inward rectifying K+ channel).
Figure 2
Figure 2. GPCR Desensitization
GRKs are recruited to and phosphorylate ligand-occupied GPCRs on the cytoplasmic carboxyl-terminal tail. β-arrestins bind phosphorylated GPCRs with enhanced affinity, thereby creating a platform for: blocking recoupling of the dissociated G-protein subunits to the GPCR, thereby preventing further receptor activation (i.e. desensitization); coordination of GRK and arrestin in assembly of macromolecular signaling complexes; recruitment of endocytotic machinery as a precursor to receptor internalization (i.e. downregulation), whence the receptor may be dephosphorylated and recycled back to the membrane or targeted for lysosomal degradation.
Figure 3
Figure 3. GRK/Gβγ Manipulation
Pictorial representation of putative regulation of GRK/Gβγ functions from recent literature. See text for details.
  1. Ref.

  2. Ref.

  3. Refs. , , , , , ,

  4. Ref.

  5. Ref.

  6. Ref.

References

    1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57:1–134. - PubMed
    1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215. - PubMed
    1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC, Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235. - PubMed
    1. Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA. 2002;287:883–889. - PubMed
    1. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451:919–928. - PubMed

Publication types

MeSH terms

Substances